Healthy
Conditions
Keywords
Eye-tracking, Losartan
Brief summary
The main aim of the present study is to investigate the effects of orally administered Losartan on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Detailed description
Animal models and initial findings in humans suggest that the angiotensin II antagonist Losartan may have neuroprotective effects and could potentially enhance cognitive functions, including valence-specific attention and regulatory control. Within this context the present study aims to examine whether angiotensin II blockade via Losartan modulates top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of Losartan (50 mg) or placebo before performing a saccade/anti-saccade task 90 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine general as well as social and emotion-specific effects of oral losartan.
Interventions
DRUGLosartan
Administration of Losartan tablets(50 mg)
DRUGPlacebo
Administration of Placebo tablets
Sponsors
University of Electronic Science and Technology of China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent. Normal or corrected-normal version
Exclusion criteria
* History of neuropsychiatric diseases. * History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness. * History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction. * History of renal diseases, including renal stones or renal failure. * History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus * Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food. * Infections such as COVID-19 or influenza, or unexplained fever. * Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg). * History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes. * Blood donation (≤ 1 month prior to administration). * Take oral contraceptives or receive hormonal medications in the three months prior to the experiment. * Pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Saccade/antisaccade latency difference between social and non-social stimuli after losartan administration | 90 minutes - 120 minutes after treatment | Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the losartan and placebo treatment conditions. |
| Error rate of saccade/antisaccade for social versus non-social stimuli after losartan administration | 90 minutes - 120minutes after treatment | Comparison between social-specific error rates of saccade/antisaccade between the losartan and placebo treatment conditions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Saccade/antisaccade latency for different facial emotions after losartan administration | 90 minutes - 120 minutes after treatment | Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the losartan and placebo treatment conditions. |
| Error rate of saccade/antisaccade for different facial emotions after losartan administration | 90 minutes - 120 minutes after treatment | Comparison between emotion-specific saccade/antisaccade error rates between the losartan and placebo treatment conditions. |
Countries
China
Contacts
Primary ContactWeihua Zhao, Dr
Outcome results
None listed